THE NEWEST TRENDS IN LUNG CANCER & MESOTHELIOMA CASES

Transcription

1 Conference Chairs: THE NEWEST TRENDS IN LUNG CANCER & MESOTHELIOMA CASES LEADING DOCTORS, SCIENTISTS & LAWYERS DISCUSS THE EPIDEMIOLOGY, BIOLOGY & PRACTICAL ISSUES THAT AFFECT CASE FILINGS, TRIALS, SETTLEMENTS, AND INSURANCE COVERAGE Wednesday, June 19, 2013 Omni Chicago Hotel Chicago, IL Christian H. Hartley, Esq., Maune, Raichle, Hartley, French & Mudd, LLC, Charleston, SC Kirk T. Hartley, Esq., LSP Group LLC, Chicago, IL Albert H. Parnell, Esq., Hawkins Parnell Thackston & Young LLP, Atlanta, GA

2 Event Agenda The Newest Trends in Lung Cancer and Mesothelioma Cases Wednesday, June 19, :30 AM Registration 9:00 AM Opening Remarks Christian H. Hartley, Esq., Maune, Raichle, Hartley, French & Mudd, LLC, Charleston, SC Kirk T. Hartley, Esq., LSP Group LLC, Chicago, IL Albert H. Parnell, Esq., Hawkins Parnell Thackston & Young LLP, Atlanta, GA 9:15 AM Where Are All the Mesotheliomas Coming from and What s Ahead The US mesothelioma numbers - what s actually happening, and predicted Global mesothelioma numbers - what s actually happening and predicted Discussion of the limits of the estimates from Dr. Nicholson and KPMG Bruce W. Case, M.D., M.Sc., Dipl. Occup. Hygiene, FRCP(C), McGill University, Montreal, Canada Current Sabbatical Leave- London School of Hygiene and Tropical Medicine, London, United Kingdom Daniel J. O Connell, Esq., O Connell, Tivin, Miller & Burns, LLC, Chicago, IL 10:15 AM Break Sponsored by: Rosetta Genomics 10:30 AM Lung Cancers, Screenings and Litigation- The Science and Law Issues Understand why lung cancer screenings are increasing outside litigation What science tells us now about lung cancer causation Why does the medical record include a personalized medicine test that talks about genetic mutation Factors lawyers should consider before investing in claims and defenses Allan Feingold, MD, FRCP(C), FCCP, Medical Director, Occupational & Environmental Medicine, South Miami Hospital, Miami, FL Edward J. McCambridge, Esq., Segal McCambridge Singer & Mahoney, Ltd., Chicago, IL Ravi Salgia, M.D., Ph.D., Professor-Department of Medicine, Section of Hematology/Oncology, The University of Chicago, Chicago, IL 11:30 AM New Science on Chrysotile and Causation, Thresholds, Fiber Burdens and Non-Asbestos Co-Factors Update and review of data on non-asbestos co-factors, including rock wool, radiation and more

3 Thoughts on parallels between asbestos fibers and non-asbestos fibers Chrysotile and causation - data updates and ongoing studies Bruce W. Case, M.D., M.Sc., Dipl. Occup. Hygiene, FRCP(C), McGill University, Montreal, Canada Current Sabbatical Leave- London School of Hygiene and Tropical Medicine, London, United Kingdom Thomas Hesterberg, Ph.D., Principal Toxicologist, Center for Toxicology and Environmental Health, Little Rock, AR Victor L. Roggli, MD, Professor of Pathology, Duke University Medical Center, Durham, NC Samuel P. Hammar, M.D., Owner/President, Diagnostic Specialty Laboratory, Inc. P.S., Bremerton, WA 12:30 PM Lunch Sponsored by: O Connell, Tivin, Miller & Burns, LLC 1:30 PM Some Mesothelioma Patients Are Living Much Longer Why, How Often and What s Ahead Will Living Meso Trials Become Common Living meso trials present risks and opportunities for both sides why are some persons with mesothelioma living much more than a year, and what individual health and genomic variables are doctors looking at to try to project the future course of disease and make treatment recommendations Some true centers of mesothelioma excellence have arrived what outcome advantages can they sometimes offer Formal mesothelioma bio-banks now exist center of excellence support will influence the future of mesothelioma data collection and treatment outcomes Genomic tumor studies are now arriving, and mesothelioma and lung tumor samples are now collected, preserved and organized in formal bio-banks - what types of data and outcomes may emerge as treatments become more personalized and genomic analysis becomes increasingly common and meaningful Allen E. Lockerman, IV, Esq., Hawkins Parnell Thackston & Young LLP, Atlanta, GA David John Sugarbaker, M.D., Chief, Division of Thoracic Surgery, Brigham and Women's Hospital, Boston, MA 2:30 PM Molecular Biomarkers Are Arriving for Mesotheliomas - Understand the Facts and Consider the Implications Biomarkers no longer are a dream - today, they exist and commercial companies want to market early screening tests to find stage 1 or 2 tumors before they become too hard to remove This panel brings together one of the nation s best treating physicians and leading commercial laboratories working on powerful tumor biomarkers one mesothelioma biomarker test already is approved for reimbursement by CMS and more mesothelioma tests may be added to the list The role of biomarkers takes on added significance in view of the announcement that the insulators union and Mt. Sinai are embarking on a new screening program to promote early detection of tumors Kirk T. Hartley, Esq., LSP Group LLC, Chicago, IL Harvey I. Pass, M.D., NYU Langone Medical Center / School of Medicine, New York, NY Rachel Ostroff, Ph.D., SomaLogic, Inc., Boulder, CO Robert Wassman, M.D., Chief Medical Officer, Rosetta Genomics, Boston, MA

4 3:30 PM Break Sponsored by: Forman Perry Watkins Krutz & Tardy LLP 3:45 PM Lung Cancer The New Claims, and New Science Lung Cancer claims are still an important component of asbestos litigation A panel of doctors and lawyers will talk about the historical trends in lung cancer litigation, and make remarks regarding new papers on lung cancer and asbestos. An update on issues central to the litigation including: lung cancer subtypes caused by exposure to asbestos, the role of smoking in causation, and exposure levels. Biotech firms are at work on commercializing reliable, molecular tests for cancers, including the use of protein cocktail test and the use or microrna, which may be used to fingerprint changes related to exposures to toxins some of the tests already are approved learn more about what s already in place and what may be possible for lung cancers. Moderator: Justin Shrader, Esq., Shrader & Associates, L.L.P., Houston, TX Allan Feingold, MD, FRCP(C), FCCP, Medical Director, Occupational & Environmental Medicine, South Miami Hospital, Miami, FL Samuel P. Hammar, M.D., Owner/President, Diagnostic Specialty Laboratory, Inc. P.S., Bremerton, WA Albert H. Parnell, Esq., Hawkins Parnell Thackston & Young LLP, Atlanta, GA Harvey I. Pass, M.D., NYU Langone Medical Center / School of Medicine, New York, NY Victor L. Roggli, MD, Professor of Pathology, Duke University Medical Center, Durham, NC Robert Wassman, M.D., Chief Medical Officer, Rosetta Genomics, Boston, MA 5:00 PM - 6:00 PM Networking Cocktail Reception Sponsored by: Hawkins Parnell Thackston & Young LLP LSP Group LLC *Speakers and Agenda are subject to change.

5 Register for the Event The Newest Trends in Lung Cancer & Mesothelioma Cases June 19, 2013 Omni Chicago Hotel, Chicago, IL All in-house counsel and insurance professionals always complimentary at Perrin Conferences. * Special Restrictions Apply. Registration Cost $895. Includes private website access to course materials, continental breakfast, lunch, refreshment breaks and networking cocktail reception. Group discounts available, please inquire. For more information or to register, contact Lynnsey Perrin ([email protected]) or Bethany Long ([email protected]). You Can Also Register On-line at: OR-Through the attached mail-in registration form at the end of this brochure. Hotel Information Omni Chicago Hotel, 676 N. Michigan Avenue, Chicago, IL Room Block: Call the Omni Hotel Reservations department at THE-OMNI ( ) and reference Perrin Conferences. The room rate is $295 for a Deluxe Suite (single and double).

6 THE NEWEST TRENDS IN LUNG CANCER AND MESOTHELIOMA CASES June 19, Chicago, IL Mail-in Registration Form Name Company/Firm Name Address City State Zip Code Telephone Fax Address Registration Fee: $895 Credit Card Number Credit Card Expiration Date Credit Card Code Please Mail Form to: Perrin Conferences, Attn: Lynnsey Perrin Hee, 200 Coldstream Drive, Berwyn, PA Make Checks Payable to: Perrin Conferences, LLC Or to: